Results 51 to 60 of about 1,436,145 (318)

Whole blood transcriptome analysis in onchocerciasis

Current Research in Parasitology and Vector-Borne Diseases, 2022
Identifying the molecular mechanisms controlling the host’s response to infection with Onchocerca volvulus is important to understand how the human host controls such parasitic infection.
Ole Lagatie, Linda Batsa Debrah, Alex Y. Debrah, Lieven J. Stuyver   +3 more
doaj   +1 more source

Aggressive prostate cancer is associated with pericyte dysfunction

Molecular Oncology, EarlyView.
Tumor‐produced TGF‐β drives pericyte dysfunction in prostate cancer. This dysfunction is characterized by downregulation of some canonical pericyte markers (i.e., DES, CSPG4, and ACTA2) while maintaining the expression of others (i.e., PDGFRB, NOTCH3, and RGS5).
Anabel Martinez‐Romero, Ane Martinez‐Larrinaga, Joaquim Grego‐Bessa, Saioa Garcia‐Longarte, Hielke van Splunder, Ianire Astobiza, Amaia Ercilla, Laura Bozal‐Basterra, Isabel Mendizabal, Pilar Villacampa, Arkaitz Carracedo, Mariona Graupera   +11 more
wiley   +1 more source

Tumor and germline testing with next generation sequencing in epithelial ovarian cancer: a prospective paired comparison using an 18‐gene panel

Molecular Oncology, EarlyView.
Genetic testing in epithelial ovarian cancer includes both germline and tumor‐testing. This approach often duplicates resources. The current prospective study assessed the feasibility of tumor‐first multigene testing by comparing tumor tissue with germline testing of peripheral blood using an 18‐gene NGS panel in 106 patients.
Elisabeth Spenard, Cristina Mitric, Melanie Care, Tracy L. Stockley, Raymond H. Kim, Jeanna McCuaig, Blaise Clarke, Laura Ranich, Clare Sheen, Sarah E. Ferguson, Liat Hogen, Taymaa May, Marcus Q. Bernardini   +12 more
wiley   +1 more source

Development of a four autophagy-related gene signature for active tuberculosis diagnosis

Frontiers in Cellular and Infection Microbiology
BackgroundTuberculosis (TB) diagnostics urgently require non-sputum biomarkers to address the limitations of conventional methods in distinguishing active TB (ATB) from latent infection (LTBI), healthy controls (HCs), and TB-mimicking diseases (ODs ...
Baoyan Ren, Feng Jia, Qixun Fang, Jingping Xu, Jingping Xu, Kangfeng Lin, Kangfeng Lin, Renhui Huang, Zhenqiong Liu, Xingan Xing, Xingan Xing   +10 more
doaj   +1 more source

A New Hematocrit Measurement Method Using a Chemiluminescence Biosensor and Its Application in a Chemiluminescence Immunoassay Platform for Myocardial Markers Detection with Whole Blood Samples [PDF]

, 2022
Huan Zhao, Han Hao, Qifeng Lin, Li Huang, Xiangyi Su, Yile Fang, Yuanying Zhang, Enben Su, Zhu Chen, Li Song, Yan Deng, Nongyue He   +11 more
openalex   +1 more source

Plasma extrachromosomal circular DNA as a biomarker in EGFR‐targeted therapy of non‐small cell lung cancer

Molecular Oncology, EarlyView.
Detection of extrachromosomal circular DNA (eccDNA) in plasma samples from EGFR‐mutated non‐small cell lung cancer patients. Plasma was collected before and during treatment with the EGFR‐tyrosine kinase inhibitor osimertinib. Plasma eccDNA was detected in all cancer samples, and the presence of the EGFR gene on eccDNA serves as a potential biomarker ...
Simone Stensgaard, Sarmad Mehmood, Eva Boysen Fynboe Ebert, Peter Meldgaard, Anindya Dutta, Boe S. Sorensen   +5 more
wiley   +1 more source

Whole blood assay to access T cell-immune responses to Mycobacterium tuberculosis antigens in healthy Brazilian individuals

Memorias do Instituto Oswaldo Cruz, 2004
The production of interferon gamma (IFNgamma) guarantees effective T cell-mediated immunity against Mycobacterium tuberculosis infection. In the present study, we simply compare the in vitro immune responses to Mycobacterium antigens in terms of IFNg ...
Paulo RZ Antas, Fernando LL Cardoso, Eliane B Oliveira, Patrícia KC Gomes, Kátia S Cunha, Euzenir N Sarno, Elizabeth P Sampaio   +6 more
doaj   +1 more source

Liquid biopsy epigenetics: establishing a molecular profile based on cell‐free DNA

Molecular Oncology, EarlyView.
Cell‐free DNA (cfDNA) fragments in plasma from cancer patients carry epigenetic signatures reflecting their cells of origin. These epigenetic features include DNA methylation, nucleosome modifications, and variations in fragmentation. This review describes the biological properties of each feature and explores optimal strategies for harnessing cfDNA ...
Christoffer Trier Maansson, Anders Lade Nielsen, Boe Sandahl Sorensen   +2 more
wiley   +1 more source

Whole-genome sequencing association analysis of quantitative red blood cell phenotypes: The NHLBI TOPMed program [PDF]

, 2021
Yao Hu, Adrienne M. Stilp, Caitlin McHugh, Shuquan Rao, Deepti Jain, Xiuwen Zheng, John Lane, Sébastian Bellefon, Laura M. Raffield, Ming‐Huei Chen, Lisa R. Yanek, Marsha M. Wheeler, Yao Yao, Chunyan Ren, Jai Broome, Jee‐Young Moon, Paul S. de Vries, Brian D. Hobbs, Quan Sun, Praveen Surendran, Jennifer A. Brody, Thomas W. Blackwell, Hélène Choquet, Kathleen A. Ryan, Ravindranath Duggirala, Nancy L. Heard‐Costa, Zhe Wang, Nathalie Chami, Michael H Preuss, Yuan‐I Min, Lynette Ekunwe, Leslie A. Lange, Mary Cushman, Nauder Faraday, Joanne E. Curran, Laura Almasy, Kousik Kundu, Albert V. Smith, Stacey Gabriel, Jerome I. Rotter, Myriam Fornage, Donald M. Lloyd‐Jones, Ramachandran S. Vasan, Nicholas L. Smith, Kari E. North, Eric Boerwinkle, Lewis C. Becker, Joshua P. Lewis, Gonçalo R. Abecasis, Lifang Hou, Jeffrey R. O’Connell, Alanna C. Morrison, Terri H. Beaty, Robert C. Kaplan, Adolfo Correa, John Blangero, Eric Jorgenson, Bruce M. Psaty, Charles Kooperberg, Russell T. Walton, Benjamin P. Kleinstiver, Tang Hua, Ruth J. F. Loos, Nicole Soranzo, Adam S. Butterworth, Debbie A. Nickerson, Stephen S. Rich, Braxton D. Mitchell, Andrew D. Johnson, Paul L. Auer, Yun Li, Rasika A. Mathias, Guillaume Lettre, Nathan Pankratz, Cathy C. Laurie, Cecelia Laurie, Daniel E. Bauer, Matthew P. Conomos, Alexander P. Reiner   +78 more
openalex   +1 more source

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

Molecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann   +15 more
wiley   +1 more source